JMP maintains Boston Scientific's underperform

Boston Scientific Corp. was maintained by JMP Securities LLC analyst Robert C. Faulkner at an underperform rating. The company's participation in a meeting of cardiologists last week, highlighting the Taxus stent, was good but not good enough. The clear majority of data still favors Johnson & Johnson's Cypher in efficacy, although both stents are tarred with safety fears, which is bad news for stents overall. Shares of the Natick, Mass.-based medical device maker were up $0.76, or 3.18%, at $24.65 on volume of 3,897,900 shares versus the three-month running average of 4,550,960 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.